Pharmacogenomics of Cytochrome P450 Family enzymes: implications for drug-drug interaction in anticancer therapy

WCRJ 2015; 2 (1): e483

Topic: Pharmacogenomics Category: Review

Di Francia R.

Hematology-Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione “G. Pascale” IRCCS, Naples, Italy
rdifrancia@iapharmagen.org Close

, Rainone A.

GORI “Gruppo Oncologico Ricercatori Italiani” Onlus, Pordenone, Italy Close

, De Monaco A.

Hematology-Oncology and Stem Cell transplantation Unit, National Cancer Institute, Fondazione “G. Pascale” IRCCS, Naples, Italy Close

, D’Orta A.

DD Clinic srl, Caserta, Italy Close

, Valente D.

CETAC Research Center, Caserta, Italy Close

, De Lucia D.

Department of Neurology, Azienda Policlinico Second University of Naples (SUN), Naples, Italy Close

Abstract

In the oncology field, predictive markers allow physicians to improve the efficacy of cancer therapy, and prognostic markers allow for selection of patients with high risk of cancer recurrence for treatment, and those with low risk of recurrence for less intensive treatment or observation only.

This review provides an overview on the commonly occurring, functionally and/or clinically relevant genetic polymorphisms within the genes encoding Cytochrome P450 (CYP) super-family. In particular, the genetic variations in the CYP2D6 gene and the pharmacokinetics and/or response of Tamoxifen-based chemotherapy have been highlighted.

Further, effective re-evaluation of drug design based on CYP enzymes may eventually be personalized and individualized to the patient for maximum efficacy of the therapies.

Free PDF Download

To cite this article